All In Biotech

Drug Trial Radar · NCT04221542

Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 505 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

505

Planned (sponsor's estimate)

Start

Mar 4, 2020

Primary completion

Jul 28, 2030

Study completion Jul 29, 2032

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
Collaborators
BeiGene; BeOne (China only)
First posted
Jan 9, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The overall aim of the trial is to evaluate the safety, tolerability, and pharmacokinetics (PK) of AMG 509 (monotherapy and in combination with abiraterone acetate and enzalutamide) and to evaluate preliminary efficacy. As of Protocol Amendment 10.2 (31 Aug 2026), only Parts 6 and 7 are open to accrual.

Conditions

  • Prostate Cancer

Interventions

  • AMG 509Drug

    AMG 509 administered as an IV infusion (Parts 1, 3, 4, 5, 6 and 7) or SC injection (Part 2).

  • AbirateroneDrug

    Abiraterone administered as oral tablets.

  • EnzalutamideDrug

    Enzalutamide administered as oral tablets.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Parts 1-5 and 7: Incidence of Treatment-emergent Adverse EventsTime frame: 3 years
  2. Parts 1-5 and 7: Incidence of Treatment-related Adverse EventsTime frame: 3 years
  3. Parts 1-5 and 7 Dose Exploration Cohorts Only: Dose Limiting Toxicities (DLTs)Time frame: 28 days
  4. Parts 1-5 and 7: Number of Participants with Changes in Vital SignsTime frame: 3 years
  5. Parts 1-5 and 7: Number of Participants with Changes in Electrocardiogram (ECG) RecordsTime frame: 3 years
  6. Parts 1-5 and 7: Number of Participants with Changes in Clinical Laboratory Test ResultsTime frame: 3 years
  7. Part 6: Objective Response (OR) per RECIST v1.1Time frame: 3 years

Locations

54 sites in 10 countries. Site status is shown where the registry gives one.

  • City of Hope National Medical Center

    Duarte, California · Recruiting

  • Providence Saint Jude Medical Center

    Fullerton, California · Recruiting

  • University of California San Francisco

    San Francisco, California · Recruiting

  • Rocky Mountain Cancer Centers

    Denver, Colorado · Recruiting

  • Emory University

    Atlanta, Georgia · Recruiting

  • Indiana University

    Indianapolis, Indiana · Recruiting

  • Tulane Medical Center

    Rochester, Minnesota · Completed

  • MidAmerica Cancer Care

    Kansas City, Missouri · Recruiting

  • Washington University

    St Louis, Missouri · Recruiting

  • Yale New Haven Hospital

    New York, New York · Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • Duke University Medical Center Duke Cancer Center

    Durham, North Carolina · Recruiting

  • Wake Forest University Health Sciences

    Winston-Salem, North Carolina · Terminated

  • Oncology Hematology Care Incorporated

    Cincinnati, Ohio · Recruiting

  • Thomas Jefferson University

    Philadelphia, Pennsylvania · Recruiting

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania · Recruiting

  • Prisma Health Upstate

    Greenville, South Carolina · Completed

  • Sanford Oncology Clinic and Pharmacy

    Sioux Falls, South Dakota · Recruiting

  • University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Virginia Oncology Associates

    Irving, Texas · Terminated

  • Intermountain Medical Center

    Murray, Utah · Recruiting

  • Virginia Cancer Specialists PC

    Fairfax, Virginia · Recruiting

  • Fred Hutchinson Cancer Center

    Seattle, Washington · Recruiting

  • Chris OBrien Lifehouse

    Camperdown, New South Wales, Australia · Recruiting

  • Monash Medical Centre

    Clayton, Victoria, Australia · Recruiting

  • Nanjing Drum Tower Hospital

    Nanjing, China · Recruiting

  • Peking University First Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China · Recruiting

  • The First Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China · Recruiting

  • Fudan University Shanghai Cancer Centre

    Shanghai, Shanghai Municipality, China · Recruiting

  • Zhejiang Provincial Peoples Hospital

    Hangzhou, Zhejiang, China · Recruiting

  • The First Affiliated Hospital of Wenzhou Medical University

    Wenzhou, Zhejiang, China · Recruiting

  • Universitaetsklinikum Essen

    Essen, Germany · Recruiting

  • Universitaetsklinikum Heidelberg

    Heidelberg, Germany · Recruiting

  • Klinikum rechts der Isar der TUM

    München, Germany · Recruiting

  • Universitaetsklinikum Muenster

    Münster, Germany · Recruiting

  • National Cancer Center Hospital East

    Kashiwa-shi, Chiba, Japan · Recruiting

  • Yokohama City University Hospital

    Yokohama, Kanagawa, Japan · Recruiting

  • The Cancer Institute Hospital of Japanese Foundation for Cancer Research

    Koto-ku, Tokyo, Japan · Recruiting

  • Hospital da Luz, SA

    Lisbon, Portugal · Recruiting

Showing 40 of 54 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.